title: [The evaluation of the effect of Estracyt on prostatic cancer].
abstract: The clinical effect of Estracyt on untreated prostatic carcinoma was evaluated. The subjects consisted of 51 of 71 patients with prostatic carcinoma who were observed for 6 months or more after oral administration of 560 mg of estramustine phosphate. This drug was effective in all patients: markedly effective in 34 (66.6%), moderately effective in 13 (25.5%), and slightly effective in 4 (7.8%). During the observation period varying from 6 months to 2 years and 6 months, 7 patients had recurrence of progression. The interval between the drug administration and recurrence of progression varied from 6 months to 1 year and 10 months (mean, 15.8 months). Prostate acid phosphatase and gamma-seminoprotein remained normal between 3 and 15 months after the administration but became elevated due to recurrence of progression after 18 months or more in some patients. Blood testosterone, luteinizing hormone, and follicle stimulating hormone decreased while blood cortisol increased. Therefore, estrogen was acting effectively. Side effects were observed in 56.9% of the patients, the most frequent being mazoplasia in 33 patients (45.8%), and cardiovascular complications and apoplexy in 11 patients (15.3%). Estracyt was effective for untreated prostatic carcinoma but the problems such as recurrence of progression and side effects require further examination.
authors.affiliation: Department of Urology, Yokohama Minami Kyosai Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Fukuoka
authors.forename: Y
authors.initials: Y
authors.lastname: Ishibashi
authors.forename: N
authors.initials: N
authors.lastname: Sakai
authors.forename: T
authors.initials: T
authors.lastname: Ogawa
authors.forename: Y
authors.initials: Y
authors.lastname: Satomi
authors.forename: T
authors.initials: T
authors.lastname: Sugawara
authors.forename: H
authors.initials: H
authors.lastname: Kamimura
authors.forename: T
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Kishida
authors.forename: K
authors.initials: K
authors.lastname: Shirai
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy*; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D002214:Capsules; D004341:Drug Evaluation; D004961:Estramustine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
chemical_list: D002214:Capsules; D004961:Estramustine; D013739:Testosterone; D006854:Hydrocortisone